https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1146362/full
Background: Efficacy and toxicities of anlotinib (ANL) show large inter-patient variation, which may partly be explained by differences in ANL exposure. Expo...
plasma concentrationfrontiersassociationanlotinibtrough
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.796625/full
In the original article, there was an error. **The median PFS was incorrectly written as 8.37 months (95% CI: 6.5-10.0 months) in the abstract**.A correction...
frontierscorrigendumanlotinibcombinedanti